SCHEMBL12865686

SCHEMBL12865686

Cn1c2ccccc2c2ccc(-c3cc(-c4cc(-c5ccc6c(c5)C(C)(C)c5ccccc5-6)cc(-c5ccc6c7ccccc7n(C)c6c5)c4)cc(-c4ccc5c(c4)C(C)(C)c4ccccc4-5)c3)cc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.48
RXRB P28702 1/20 0.48
L3MBTL1 Q9Y468 3/20 0.43
GPR3 P46089 1/20 0.42
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
KIF11 P52732 1/20 0.40
HPGD P15428 4/20 0.40
KDM4E B2RXH2 4/20 0.40
ALDH1A1 P00352 3/20 0.40
HSD17B10 Q99714 3/20 0.40
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
MAPT P10636 4/20 0.38
LMNA P02545 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
ATM Q13315 1/20 0.37
PKM P14618 1/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18565372 0.97 RXRA (0.50) RXRARXRBL3MBTL1GPR3NPC1
SCHEMBL14478583 0.93 RXRA (0.44) RXRARXRBL3MBTL1GPR3NPC1
SCHEMBL13433076 0.89 GPR3 (0.44) RXRARXRBL3MBTL1GPR3NPC1
SCHEMBL13488165 0.86 RXRA (0.40) RXRARXRBL3MBTL1GPR3NPC1
SCHEMBL18565399 0.86 RXRA (0.39) RXRARXRBL3MBTL1NPC1RAB9A
SCHEMBL22707760 0.86 RXRA (0.40) RXRARXRBL3MBTL1GPR3NPC1
SCHEMBL18565368 0.85 RXRA (0.48) RXRARXRBL3MBTL1GPR3NPC1
SCHEMBL14478584 0.85 PDK2 (0.38) RXRARXRBL3MBTL1GPR3HPGD
SCHEMBL13506803 0.84 RXRA (0.37) RXRARXRBL3MBTL1NPC1RAB9A
SCHEMBL12865681 0.84 L3MBTL1 (0.44) RXRARXRBL3MBTL1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7883786-B2 highly efficient and highly luminescent optical power and is superior in durability CANON KABUSHIKI KAISHA (JP) 2011-02-08 US disclosed
US-7883786-B2 highly efficient and highly luminescent optical power and is superior in durability CANON KABUSHIKI KAISHA (JP) 2011-02-08 US disclosed
US-20080297034-A1 BIPHENYL DERIVATIVE AND ORGANIC LIGHT-EMITTING ELEMENT USING SAME CANON KABUSHIKI KAISHA (JP) 2008-12-04 US disclosed
US-20080297034-A1 BIPHENYL DERIVATIVE AND ORGANIC LIGHT-EMITTING ELEMENT USING SAME CANON KABUSHIKI KAISHA (JP) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080297034-A1 BIPHENYL DERIVATIVE AND ORGANIC LIGHT-EMITTING ELEMENT USING SAME LEF1, CYP1B1, ESR1 RXRA 662/4885RXRB 632/4885L3MBTL1 781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.